{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:03:25Z","timestamp":1791975805042,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    Netherton syndrome (NS) is a rare and potentially life-threatening genetic skin disease responsible for skin inflammation and scaling, hair abnormalities and severe allergic manifestations. NS is caused by loss-of-function variants in Serine Peptidase Inhibitor Kazal-Type 5 (\n                    <jats:italic>SPINK5<\/jats:italic>\n                    )\n                    <jats:italic>,<\/jats:italic>\n                    encoding the serine protease inhibitor LEKTI. NS patients have a profound skin barrier defect caused by unopposed kallikrein-related proteases activity (KLKs). They develop severe skin inflammation with eczematous-like lesions and high serum IgE levels. Multiomics studies have revealed that the IL-17\/IL-36 pathway is the most predominant upregulated pathway in NS. It is associated with a Th2 signature with complement activation in the ichthyosis linearis circumflexa subtype, and with interferon and Th9 activation in the scaly erythrodermic form. Several case reports proved the efficacy of different biotherapies targeting IL-17A, IL-12\/IL-23, IL-4R and IL-13R, TNF-a and IL-1\u03b2 in pediatric NS patients. Intravenous immunoglobulins (IVIG) have also shown efficacy. These studies showed no severe side effects. At present, IL-17 blockade seems to be the most efficient treatment, but case reports remain limited with small numbers of patients and no placebo-control. Additional pathways must also be explored, and more efficient strategies could be used to block IL-17 and IL-23 pathways. In the future, the combination of specific strategies aiming at repairing the initial skin barrier defect could potentiate the efficacy of biologics. The current reports suggest that biological therapy is safe and often effective at pediatric age. However, controlled clinical trials that include a larger number of patients need to be conducted to reach more reliable conclusions.\n                  <\/jats:p>","DOI":"10.3389\/fped.2022.1074243","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:29:05Z","timestamp":1671784145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Biological treatments for pediatric Netherton syndrome"],"prefix":"10.3389","volume":"10","author":[{"given":"Matteo","family":"Pontone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Filippeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Oranges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto Andrea","family":"Pedaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Barni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Barbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Consonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Indolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Azzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Hovnanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.645259","article-title":"Netherton syndrome in children: management and future perspectives","volume":"9","author":"Barbati","year":"2021","journal-title":"Front Pediatr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/21678707.2020.1857724","article-title":"Advances in understanding of netherton syndrome and therapeutic implications","volume":"8","author":"Petrova","year":"2020","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"158673","DOI":"10.1016\/j.bbalip.2020.158673","article-title":"Skin of atopic dermatitis patients shows disturbed \u03b2-glucocerebrosidase and acid sphingomyelinase activity that relates to changes in stratum corneum lipid composition","volume":"6","author":"Boer","year":"2020","journal-title":"Biochim Biophys Acta - Mol Cell Biol Lipids"},{"key":"B4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.0022-202X.2005.23838.x","article-title":"Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and Stratum corneum integrity","volume":"125","author":"Hachem","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jaci.2014.05.048","article-title":"Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis","volume":"134","author":"Elias","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jaci.2016.07.019","article-title":"An IL-17\u2013dominant immune profile is shared across the major orphan forms of ichthyosis","volume":"139","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jaad.2020.07.054","article-title":"Duality of netherton syndrome manifestations and response to ixekizumab","volume":"84","author":"Barbieux","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"B9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jaci.2021.08.024","article-title":"Netherton syndrome subtypes share IL-17\/IL-36 signature with distinct IFN-\u03b1 and allergic responses","volume":"149","author":"Barbieux","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamadermatol.2020.1019","article-title":"Secukinumab therapy for netherton syndrome","volume":"156","author":"Luchsinger","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jdcr.2020.04.025","article-title":"Successful use of secukinumab in netherton syndrome","volume":"6","author":"Blanchard","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/ajd.13880","article-title":"Secukinumab use in the treatment of Netherton's Syndrome","volume":"63","author":"Gan","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/bjd.18892","article-title":"Successful treatment of netherton syndrome with ustekinumab in a 15-year-old girl","volume":"183","author":"Volc","year":"2020","journal-title":"Br J Dermatol [Internet]"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/jdv.16883","article-title":"Response to dupilumab in two children with netherton syndrome: improvement of pruritus and scaling","volume":"35","author":"S\u00fc\u00dfmuth","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jdermsci.2021.03.003","article-title":"Successful dupilumab treatment for ichthyotic and atopic features of netherton syndrome","volume":"102","author":"Murase","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/pde.14590","article-title":"Infliximab therapy in an infant with netherton syndrome","volume":"38","author":"Cicek","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000525987","article-title":"Treatment experiences with intravenous immunoglobulins, ixekizumab, dupilumab, and anakinra in netherton syndrome: a case series","author":"Ragamin","year":"2022","journal-title":"Dermatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaci.2009.06.009","article-title":"Com\u00e8l-Netherton syndrome defined as primary immunodeficiency","volume":"124","author":"Renner","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B20","year":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1111\/pde.12856","article-title":"Netherton syndrome mimicking pustular psoriasis: clinical implications and response to intravenous immunoglobulin","volume":"33","author":"Small","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1600","DOI":"10.1002\/mgg3.1600","article-title":"Netherton syndrome caused by compound heterozygous mutation, c.80A\u2009>\u2009G mutation in SPINK5 and large-sized genomic deletion mutation, and successful treatment of intravenous immunoglobulin","volume":"9","author":"Zhang","year":"2021","journal-title":"Mol Genet Genomic Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/pde.14318","article-title":"A novel SPINK5 mutation and successful subcutaneous immunoglobulin replacement therapy in a child with netherton syndrome","volume":"37","author":"Zelieskova","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s10875-011-9645-0","article-title":"Subcutaneous immunoglobulin replacement therapy with hizentra \u00ae is safe and effective in two infants","volume":"32","author":"Gallagher","year":"2012","journal-title":"J Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13816","article-title":"Managing syndromic congenital ichthyosis at a tertiary care institute\u2014genotype-phenotype correlations, and novel treatments","volume":"33","author":"Dabas","year":"2020","journal-title":"Dermatol Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/08923973.2015.1115518","article-title":"A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels","volume":"38","author":"Yalcin","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/1346-8138.16253","article-title":"Successful treatment of netherton syndrome with dupilumab: a case report and review of the literature","volume":"49","author":"Wang","year":"2022","journal-title":"J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","author":"Mills","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B30","year":""},{"key":"B31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/ijms11030789","article-title":"Interleukin 12 a key immunoregulatory cytokine in infection applications","volume":"11","author":"Hamza","year":"2010","journal-title":"Int J Mol Sci"},{"key":"B32","year":""},{"key":"B33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1365-2249.1998.00690.x","article-title":"IL-4: role in disease and regulation of production","volume":"113","author":"Choi","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/1521-1878(200007)22:7%3C646::AID-BIES7%3E3.0.CO;2-9","article-title":"The role of interleukin-13 in infectious diseases and allergy","volume":"22","author":"Brombacher","year":"2000","journal-title":"BioEssays"},{"key":"B35","year":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and related cytokines in the regulation of inflammation and immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"key":"B37","year":""},{"key":"B38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3%3C184::AID-JEMT2%3E3.0.CO;2-H","article-title":"TNF? And the TNF receptor superfamily: structure-function relationship(s)","volume":"50","author":"Idriss","year":"2000","journal-title":"Microsc Res Tech"},{"key":"B39","year":""},{"key":"B40","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/all.14197","article-title":"Comel-Netherton syndrome: a local skin barrier defect in the absence of an underlying systemic immunodeficiency","volume":"75","author":"Stuvel","year":"2020","journal-title":"Allergy"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1074243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:29:07Z","timestamp":1671784147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1074243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":40,"alternative-id":["10.3389\/fped.2022.1074243"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1074243","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"article-number":"1074243"}}